Evidence map›Paper›PMID 32069381›Full record

ArticleFEBS open bio2020

From astrocytoma to glioblastoma: a clonal evolution study.

Fuhua Yang, Yunding Zou, Qiang Gong, Jieping Chen, Wei-Dong Li, Qilin Huang

Open access · goldAbstract readCase Reports
In one paragraph

Article in FEBS open bio, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Advancements in Drug Delivery Systems in Glioblastoma Therapy.International journal of molecular sciences · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Fuhua YangDepartment of Genetics, School of Basic Medical Sciences, Tianjin Medical University, China.
Yunding ZouDepartment of Hematology, Southwest Hospital, The Army Medical University, Chongqing, China.
Qiang GongDepartment of Hematology, Southwest Hospital, The Army Medical University, Chongqing, China.
Jieping ChenDepartment of Hematology, Southwest Hospital, The Army Medical University, Chongqing, China.
Wei-Dong LiDepartment of Genetics, School of Basic Medical Sciences, Tianjin Medical University, China.ORCID 0000-0003-0521-7412
Qilin HuangDepartment of Neurosurgery, Xinqiao Hospital, The Army Medical University, Chongqing, China.ORCID 0000-0003-0774-0610
Army Medical University · CNTianjin Medical University · CNTianjin Medical University Eye Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Astrocytomas often recur after surgical resection, but the underlying mechanism remains enigmatic. Elucidation of clonal evolution in primary and relapse tumors may provide important information on tumor progression. Here, we examined genetic factors underlying recurrence in a patient with astrocytoma initially diagnosed with World Health Organization (WHO) grade II astrocytoma, who then relapsed with glioblastoma (WHO grade IV) complicated with local anaplastic astrocytoma (WHO grade III). We performed genomic DNA sequencing and data analysis of paired tumor tissue specimens and a peripheral blood sample (control), and used expands software for subclone analysis. A germline NOTCH1 missense mutation was identified in the peripheral blood sample, the primary tumor and the relapse tumor; in addition, we identified a tumor protein p53 (TP53) heterozygous nonsense mutation in the primary tumor and a TP53 homozygous nonsense mutation and an IDH1 heterozygous missense mutation in the relapse tumor. Clonal evolution trees indicated higher heterogeneity in the relapse tumor. Although germline mutations might contribute to the driving force of the primary tumor, aggressive chemotherapy and radiation may apply selective pressure for tumor clonal evolution; furthermore, a total loss of function of gatekeeping genes (TP53) may result in impaired DNA repair and catastrophic chromosomal aberrations.

Indexed as

AdultAstrocytomaBase SequenceClonal EvolutionDisease ProgressionDNA, NeoplasmFemaleGenes, p53Germ-Line MutationGlioblastomaHumansIsocitrate DehydrogenaseMutationNeoplasm Recurrence, LocalReceptor, Notch1RecurrenceDNA, NeoplasmIDH1 protein, humanIsocitrate DehydrogenaseNOTCH1 protein, humanReceptor, Notch1TP53 protein, humanTumor Suppressor Protein p53astrocytomaclonal evolutionglioblastomarelapseTP53

Identifiers

PMID32069381
PMCPMC7193157
OpenAlexW3007930130

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.